Syncona sells Gyroscope to Novartis for up to $1.5bn
Syncona Limited NPV
93.30p
12:59 10/01/25
2.30%
2.10p
Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.
Equity Investment Instruments
12,171.14
12:59 10/01/25
-0.29%
-35.52
FTSE 250
19,865.19
13:00 10/01/25
n/a
n/a
FTSE 350
4,541.87
13:00 10/01/25
n/a
n/a
FTSE All-Share
4,496.78
13:00 10/01/25
n/a
n/a
The company said it would receive an upfront payment of $800m, with another $700m potentially on offer via milestone payments related to clinical development, regulatory approvals and reimbursement.
On closing, the deal is expected to result in cash proceeds of £334m for Syncona, representing a £180m uplift to previous valuation and internal rate of return of 55%.
The sale could also generate a further £255m through future milestone payments, which if received would take total proceeds to £589m.